邮件订阅 RSS 中文 | English
高级检索
夏盈峰, 伊弘元, 金博茹, 等. 阿尔茨海默病患者血浆鸟氨酸浓度与认知功能的相关性及其对认知功能下降的诊断价值[J]. 中国临床医学, 2023, 30(2): 209-214. DOI: 10.12025/j.issn.1008-6358.2023.20222309
引用本文: 夏盈峰, 伊弘元, 金博茹, 等. 阿尔茨海默病患者血浆鸟氨酸浓度与认知功能的相关性及其对认知功能下降的诊断价值[J]. 中国临床医学, 2023, 30(2): 209-214. DOI: 10.12025/j.issn.1008-6358.2023.20222309
shu
XIA Ying-feng, YI Hong-yuan, JIN Bo-ru, et al. Correlation between plasma ornithine concentration and cognitive function in patients with Alzheimer disease and its diagnostic value in cognitive impairment[J]. Chin J Clin Med, 2023, 30(2): 209-214. DOI: 10.12025/j.issn.1008-6358.2023.20222309
Citation: XIA Ying-feng, YI Hong-yuan, JIN Bo-ru, et al. Correlation between plasma ornithine concentration and cognitive function in patients with Alzheimer disease and its diagnostic value in cognitive impairment[J]. Chin J Clin Med, 2023, 30(2): 209-214. DOI: 10.12025/j.issn.1008-6358.2023.20222309
shu

阿尔茨海默病患者血浆鸟氨酸浓度与认知功能的相关性及其对认知功能下降的诊断价值

Correlation between plasma ornithine concentration and cognitive function in patients with Alzheimer disease and its diagnostic value in cognitive impairment

    摘要
  • 摘要:
    目的 探讨阿尔茨海默病(Alzheimer disease, AD)患者外周血鸟氨酸浓度的变化, 分析其与简易精神状态检查(Mini-Mental State Examination, MMSE)量表的相关性以及对认知功能下降的诊断价值。
    方法 收集2020年10月至2022年1月就诊于复旦大学附属中山医院的26例经18F-AV45 PET确诊的AD患者(AD组)及30例社区同龄健康受试者(对照组)外周血样本, 使用试剂盒对血浆鸟氨酸浓度进行测定。采用Pearson相关性分析评价血浆鸟氨酸浓度与MMSE评分的相关性; 采用多元线性回归方程建立血浆鸟氨酸浓度、年龄、性别对MMSE评分影响的预测模型; 采用受试者工作特征(receiver operating characteristic, ROC)曲线分析血浆鸟氨酸浓度对认知功能下降的诊断价值。
    结果 AD组平均血浆鸟氨酸浓度为(458.55±17.90)μmol/L, 显著低于对照组(640.21±36.48)μmol/L, P < 0.001。Pearson相关性分析显示血浆鸟氨酸浓度与MMSE评分正相关(r=0.437 9, P=0.000 7), 多元回归分析显示血浆鸟氨酸浓度是MMSE评分的影响因素(β=0.202, P=0.001)。ROC曲线显示血浆鸟氨酸浓度诊断认知功能下降的最佳临界值为557.58 μmol/L, 灵敏度为70%, 特异度为88.5%。
    结论 AD患者血浆鸟氨酸浓度显著低于健康受试者, 且与MMSE评分正相关, 鸟氨酸浓度下降是MMSE评分降低的危险因素; 血浆鸟氨酸浓度有助于诊断AD患者认知功能下降。

     

    Abstract:
    Objective To explore the changes of ornithine concentration in peripheral blood of patients with Alzheimer disease (AD), and to analyze the correlation between ornithine concentration and Mini-Mental State Examination (MMSE) score, and its diagnostic value in cognitive impairment.
    Methods Peripheral blood samples of 26 AD patients (AD group) with positive images of 18F-AV45 positron emission tomography (PET) from Zhongshan Hospital, Fudan University and 30 healthy controls (control group) from community were collected from October 2020 to January 2022, and the plasma ornithine concentration was determined by the ornithine kit.The correlation between plasma ornithine concentration and MMSE score was evaluated by Pearson correlation analysis.Multiple linear regression model was established to analyze the effect of plasma ornithine concentration, age and sex on MMSE score.The diagnostic effect of plasma ornithine concentration on cognitive impairment was analyzed by receiver operating characteristic (ROC) curve.
    Results The average ornithine concentration was (458.55±17.90)μmol/L in AD group and (640.21±36.48)μmol/L in control group.The difference between the two groups was statistically significant (P < 0.001).Pearson correlation analysis showed that there was a positive linear correlation between plasma ornithine concentration and MMSE (r=0.437 9, P=0.000 7).Multivariate regression analysis showed that the plasma ornithine concentration had an significantly effect on MMSE score (β=0.202, P=0.001).ROC curve analysis showed that the optimal cut-off value of plasma ornithine concentration for cognitive impairment was 557.58 μmol/L, the sensitivity was 70.0% and the selectivity was 88.5%.
    Conclusions The plasma ornithine concentration in AD patients is lower than that in healthy controls, which is positively correlated with MMSE score.In addition, plasma ornithine concentration has a certain diagnostic value in evaluating the cognitive impairment.

     

    • HTML全文
    • 参考文献(24)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回